Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Part of paid clinical trials in Columbus, Ohio.

Sponsor: Ritu Salani
Study ID: NCT01219777
Phase: PHASE1
Status: Completed

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Eligibility Criteria

Sex: FEMALE
Age: 18 Years - 90 Years
Healthy Volunteers: Not accepted

Interventions

carboplatin — DRUG
Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Bevacizumab — DRUG
Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
Paclitaxel — DRUG
60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.

Study Details

The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.